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Purpose: To investigate the therapeutic effectiveness of ultrasound (US)-guided 
trigger point injection for myofascial trigger points (MTrPs) in the internal rotator 
muscles of the shoulder in post-mastectomy patients. Materials and Methods: 
This pilot study was a non-controlled, prospective, clinical trial. Nineteen post-
mastectomy patients with a diagnosis of at least one active MTrP in the subscapu-
laris and/or pectoralis muscles were included. We performed trigger point injections 
into the subscapularis muscle deep behind the scapula as well as the pectoralis mus-
cle for diagnostic and therapeutic purpose by the newly developed US-guided 
method. Results: Visual analogue scale and range of motion of the shoulder for 
external rotation and of abduction showed significant improvement immediately 
after the first injection and 3 months after the last injection compared with baseline 
(p<0.05 for both). Duration from onset to surgery and duration of myofascial pain 
syndrome in the good responder group were significantly shorter than in the bad 
responder group (p<0.05). Patients did not report any complications related to the 
procedure or serious adverse events attributable to the treatment. Conclusion: In 
post-mastectomy patients with shoulder pain, US-guided trigger point injections of 
the subscapularis and/or pectoralis muscles are effective for both diagnosis and 
treatment when the cause of shoulder pain is suspected to originate from active 
MTrPs in these muscles, particularly, the subscapularis.
Key Words:   Myofascial pain syndrome, ultrasound, breast cancer, trigger points, 
pain
INTRODUCTION
 
Women diagnosed with breast cancer can expect substantially better survival rates 
than those with other common cancers, although breast cancer remains the leading 
form of cancer in women. The high incidence rate along with relatively favorable 
survival rate makes the quality of survival important.1 Especially, breast cancer pa-
tients with shoulder and arm pain have significantly decreased quality of life com-
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serve the subscapularis muscle with MTrPs for trigger point 
injections on ultrasonography, if the patient is placed in the 
supine position with the shoulder flexed, externally rotated 
and abducted with the scapula rotated upwardly.9
This study applied a novel position--the supine position 
with the scapula rotated upwardly--for post-mastectomy pa-
tients with MPS in the subscapularis muscles. Hence, this 
study aimed to investigate the therapeutic effectiveness of 
US-guided trigger point injection for active MTrPs in the 
internal rotator muscles of the shoulder in patients who are 
status post breast cancers surgery. This study was designed 
to test following hypotheses: 
We performed accurate trigger point injections into the 
subscapularis muscle deep behind the scapula as well as 
into the pectoralis muscle for the purposes of diagnosis and 
treatment using the newly developed US-guided method.
MATERIALS AND METHODS
　　　
Participants
The potential participants of this study were women older 
than 18 years with post-mastectomy who were referred to the 
physiatrist (S.C.L) for shoulder pain between April 2011 and 
June 2012. To be eligible for the study, participants fulfilled 
the following criteria: 1) diagnosis of breast cancer (grades I 
to IIIB); 2) postmastectomy state for at least 6 months with-
out current sign of recurrence; 3) at least 3 months after adju-
vant treatment (radiation, chemotherapy); 4) suffered shoul-
der/axillary pain that began after the breast cancer surgery; 
5) diagnosis of MPS in the internal rotator muscle (sub-
scapularis and/or pectoralis) of the shoulder. Exclusion cri-
teria included: 1) bilateral breast cancer; 2) MPS in other 
muscles than the subscapularis or pectoralis muscle; 3) re-
ceived other therapeutic modalities such as analgesic, phys-
ical therapies or different types of injections during study 
periods; 4) neurologic shoulder/axillary pain, if the patient 
had a history of posterior neck pain; 5) signs and symptoms 
of neuropathy in the upper limbs; and 6) a 0-10 range visu-
al analogue scale (VAS) score <5. Diagnosis of MPS was 
based on the modified criteria described by Simons10 The 
criteria were: 1) tender spots in the subscapularis or pecto-
ralis muscle; 2) typical pattern of referred pain elicited when 
tender spots are compressed; 3) restricted ROM; and 4) 
LTRs during US-guided trigger point injections.11
This study was approved by the Institutional Review 
Board and human subjects review committee before the 
pared to women without breast cancer, as well as breast 
cancer patients who do not have shoulder and arm pain.2 
Different diagnoses, such as rotator cuff disease, myofascial 
trigger point (MTrP), adhesive capsulitis, axillary web syn-
drome, and lateral epicondylitis have been used to describe 
shoulder and arm pain among breast cancer patients.3,4
An MTrP is a highly localized painful or sensitive spot 
located in a palpable taut band of skeletal muscle fibers in 
patients with myofascial pain syndrome (MPS).5 Pain from 
active MTrPs can occur spontaneously or in response to 
movement. A latent MTrP is defined as a sensitive spot at 
which pain or discomfort is elicited by compression only. 
The diagnosis of MPS, which manifest with one or more 
active MTrP, usually is based on the patient’s subjective 
symptoms and the presence of an active MTrP character-
ized by 1) tender spots in one or more palpable taut band, 
2) a referred pain pattern, 3) a local twitch response (LTR), 
and 4) restricted range of motion (ROM).6 Myofascial tis-
sues have been implicated in the origin of shoulder pain.7 In 
this context, MPS has been a potential cause of chronic 
pain in breast cancer survivors who have undergone breast 
cancer surgery.5 In their study, MPS on the pectoralis major, 
infraspinatus and upper trapezius were highly prevalent.
We have recently observed a significant number of pa-
tients with post-mastectomy who were compatible with the 
criteria of MPS in the subscapularis muscle as well as the 
pectoralis muscle, as assessed by careful physical examina-
tion. However, trigger point injection into the subscapularis 
is difficult without neurovascular injury or incorrect injec-
tion to the muscles other than the subscapularis because of 
its deep location. An ultrasound (US)-guided injection tech-
nique into the suscapularis muscle was introduced for the 
treatment of spasticity.8 In this approach, the patient as-
sumed the lateral decubitus position with the affected side 
up and US-guided injections into motor points were per-
formed safely and accurately. However, trigger point injec-
tions differ in terms of a multiple number of needlings for 
variable locations of MTrPs, in contrast to less variable loca-
tions of motor points between patients with spastic subscap-
ularis. Therefore, patient positions for motor point injections 
for spastic subscapularis muscles would not be appropriate 
for trigger point injections for MTrPs in the subscapularis 
muscle. Patients with MPS in the shoulder experience less 
limitation of motion, especially in the scapular upward rota-
tion, compared to spastic shoulders. While the lateral decu-
bitus position is appropriate to expose the subscapularis 
muscle in the spastic shoulder, it would be sufficient to ob-
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study began. Written informed consent was obtained from 
all participants after they were briefed on the purpose and 
procedures of the study.
US-guided injection procedure
All patients had a diagnosis of at least one active MTrP in 
the subscapularis and/or pectoralis muscle based on the pre-
viously outlined criteria. US-guided trigger point injection 
methods have been previously reported for lower back 
muscles and were modified for MTrPs in the subscapularis 
or pectoralis.8,11
We performed B-mode, real-time ultrasonography with 
sterile coupling gel and a latex-free transducer cover using an 
Accuvix XG US machine (Medison Co., Seoul, Korea) in-
terfaced with a 5- to 12-MHz linear array transducer around 
the targeted muscle. A physiatrist (S.C.L) with more than 8 
years of experience in musculoskeletal ultrasonography 
carried out US-guided injection procedures.
For procedures involving the pectoralis muscle, the pa-
tient lay supine with the arm at side and the hand supinated. 
For procedures involving the subscapularis muscle, the pa-
tient lay supine with the shoulder abducted, elbow flexed, 
hand supinated, and scapula rotated as upwardly as possible 
to expose the subscapularis (Fig. 1). In this position, only 
the teres major muscle was located above the subscapularis. 
The pectoralis major and latissimus dorsi were not placed 
in the treatment window.
The region was scanned and a transverse plane was ob-
tained to visualize the target muscle with tender spots in the 
subscapularis or pectoralis muscle. In case of multiple ten-
der spots in one muscle, US scanning and injection proce-
dures were repeated for all tender spots. In contrast to the 
pectoralis muscle, the depth of the subscapularis muscle ne-
cessitated localization using ultrasonography (Fig. 2). First, 
the lateral border of the scapula was identified by ultraso-
nography (Fig. 3). As the subscapularis was visualized on 
US, the probe traced sites for trigger point injection (Fig. 4). 
A color Doppler images were used to avoid the neurovascu-
lar bundle. The Doppler setting changed at the level where 
vascular structures were optimally visualized in each subject. 
Under US-guidance, a 25-gauge, 3.8-cm needle connected to 
a 5-mL syringe containing 0.5% lidocaine was inserted into 
the pectoralis at the MTrPs region, and a 23-gauge, 6.0-cm 
needle connected to a 5-mL syringe was used for the sub-
scapularis muscles. A physiatrist observed LTRs on ultraso-
nography while performing trigger point injections (Sup-
plementary video 1 and 2). With the use of a short axis 
Fig. 1. Patient position for the subscapularis. The patient lay supine with the 
shoulder abducted, elbow flexed, hand supinated, and the scapula rotated 
as upwardly as possible to move the inferior angle away from the midline. 
The circles indicate the area of ultrasound examination for trigger point in-
jection of the subscapualris compared with the square for the pectoralis 
muscle.
Fig. 2. A trasverse plane ultrasound image of the pectoralis muscle. This 
superficial muscle was easily detected on ultrasound image. Pmj, pectora-
lis major; Pmi, pectoralis minor; R, rib.
Fig. 3. A trasverse plane ultrasound image of the subscapularis muscle. 
Before the trigger point injection, the lateral border of the scapula needs to 
be identified. C chest wall, L lateral border of the scapula. Tmj, Teres major; 
Tmi, Teres minor; SSC, subscapularis.
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ROM of the shoulder for external rotation and of abduction 
did not show normal distribution (p<0.05 by the Shapiro-
Wilk test). Therefore, the Wilcoxon signed rank test with 
Bonferroni correctionwas used to analysis the effect of trig-
ger point injection.
All participants were divided into good responder who 
showed 4 or below 4 and bad responder who showed more 
than 4 in immediate VAS after the first trigger point injec-
tion. Mann-Whitney U test or chi-square test was used to 
compare demographic and clinical characteristics between 
the good and bad responder group. For the analysis, the 
types of surgery were grouped into mastectomy (modified 
radical mastectomy and nipple-areola complex sparing total 
mastectomy) and partial mastectomy (breast conserving sur-
gery). Statical significance was assumed to be at p<0.05.
RESULTS
 
Between April 2011 and June 2012, 78 women with breast 
cancer who underwent surgery were referred to a physiat-
rist (S.C.L) for shoulder/axillary pain. Of these, nineteen 
women met the eligibility criteria. Follow-up evaluation at 
3 months after the last trigger point injection was available 
for all 19 patients (age range, 30-76 years). Demographic 
and clinical characteristics of patients are summarized (Ta-
ble 1). The average±SD of the number of trigger point in-
jections was 2.7±1.3. The subscapularis muscle was affect-
ed in all 19 patients and the pectoralis muscle was affected 
in six of the 19 patients. In all affected muscles, LTRs were 
observed during US-guided trigger point injections. No pa-
view of the needle tip (coaxial method), the needle passing 
through the skin and adipose tissue to penetrate the muscle 
was visualized. Repeated needling was performed to differ-
ent loci in that region to elicit as many LTRs as possible. If 
no LTR was observed after 8 to 10 attempts, needling was 
stopped. At that point, a drop of 0.5% lidocaine was inject-
ed to reduce post-needling soreness. The injection site was 
pressed to ensure proper homeostasis after the procedure.
US-guided trigger point injections were performed in all 
affected muscles at 1-week intervals. Additional injections 
were not considered if patients were satisfied with the reduc-
tion in discomfort or pain severity, or if the patient did not 
want another injection for other reasons. No other therapies, 
such as physical therapy or medications, were allowed dur-
ing the study period, so as not to affect the results. However, 
self-exercise and behavior correction were allowed to avoid 
early recurrence of pain after trigger point injections. The 
patients were taught to do self-exercise comprising stretch-
ing exercise (repeated 20 times during a day) to alleviate 
MTrPs and to avoid the posture that might aggravate the 
symptoms.
Assessments
The primary outcome measures were pain intensity during 
the passive external rotation of the affected shoulder. Pain 
intensity was described by the patient on a VAS of 0-10, for 
which 0 signified no pain and 10 signified the most severe 
pain ever experienced. Secondary outcome measures were 
the passive ROM of the shoulder for external rotation and 
abduction using goniometry while in a seated position. In 
addition, we reviewed and monitored any side effects of 
trigger point injections throughout the study. Outcome mea-
surements were made at baseline, immediately after the 
first injection and 3 months after the last injection by a clin-
ical researcher who was not blinded to the study.
Demographic data were collected on all patients including 
age, body mass index, information regarding breast cancer, 
and medical history. In addition, data were collected regard-
ing the type of surgery performed, type of lymph node dis-
section, use of adjuvant treatment, lymphedema, and rota-
tor cuff tear.
Statistics
SPSS version 20.0 software (SPSS Inc, Chicago, IL, USA) 
was used for the statistical analyses. Shapiro-Wilk test was 
used for all continuous variables for determining whether 
or not the distribution was normal. The results of VAS and 
Fig. 4. The transducer of ultrasound (US) was moved from lateral to medial. 
Then, the subscapularis muscle needed to be optimally visualized under 
US-guidance to perform trigger point injections. L, lateral border of the 
scapula; SSC, subscapularis.
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onset to surgery and the duration of MPS in the good re-
sponder group were significantly shorter than the bad re-
sponder group (p<0.05).
DISCUSSION
To our best knowledge, this is the first report of US-guided 
trigger point injections into MTrPs in the subscapularis and 
pectoralis muscles, in post mastectomy patients. Treatment 
with a trigger point injection of the subscapularis and/or 
pectoralis muscles experienced relief of the symptoms in 
74% of the patients after the first trigger point injection, re-
gardless of other associated factors. As we performed trig-
ger point injections under US-guidance and observed LTRs 
(one of the objective signs of MTrPs), we could exclude the 
possibility of an injection outside the targeted muscle lead-
ing to a satisfactory response. In case of MTrPs in the sub-
scapularis and/or the pectoralis major after breast cancer 
surgery, treatment effects decreased as treatment was de-
layed. Therefore, early intervention is required for MTrP in 
tient was affected only in the pectoralis muscle. At baseline, 
in patients in whom MTrPs existed simultaneously in the 
pectoralis and subscapularis muscles, pain severity was 
greater and ROM of shoulder external rotation and abduc-
tion were more restricted, compared to patients with MTrPs 
in the subscapularis muscle only (p<0.05). However, re-
sponses to treatment were not very different.
VAS and ROM of the shoulder for external rotation and 
of abduction showed significant improvement immediately 
after the first injection and at 3 months after the last injec-
tion compared with baseline (p<0.05) (Table 2). Treatment 
effects decreased as treatment was delayed, initial pain se-
verity was high, and limitation of ROM of the shoulder was 
severe (p<0.05). Patients did not report any complications 
related to the procedure or serious adverse events attribut-
able to the treatment. There were no infections or vascular 
injuries.
There was no significant difference in demographic and 
clinical characteristics including cancer stage, method of 
operation and history of adjuvant therapy between the good 
and the bad responder group. However, the duration from 
Table 1. Baseline Characteristics of the 19 Patients
Patient 
No.
Surgical 
procedure
Lympho 
node 
dissection
Duration 
since 
surgery 
(months)
Duration 
of pain 
(m)
Cancer 
stage
Adjuvant therapy Treated muscles
RT CT HT Subscapularis
Pectoralis 
major
  1 MRM ALND 16   7 IIIB Y Y Y X X
  2 MRM ALND 12   3 IIB Y X
  3 BCS SLNB 42 24 IIA Y Y Y X
  4 BCS ALND 11   4 IIIB Y Y X X
  5 BCS SLNB 24   6 I Y Y X X
  6 MRM ALND   6   2 IIIB Y X
  7 BCS SLNB 15   8 I Y Y Y X
  8 MRM SLNB 32 11 IIA Y Y X
  9 BCS SLNB 19   5 I Y Y X X
10 BCS SLNB   9   4 IIA Y Y Y X
11 NACPM ALND 11   3 IIIA Y Y Y X X
12 BCS ALND 18 12 IIB Y Y X
13 NACPM SLNB 15   6 IIA Y X
14 BCS SLNB 36 24 I Y Y X X
15 BCS SLNB   5   1 I Y X
16 BCS SLNB   7   1 IIA Y X
17 BCS SLNB   6   1 I Y Y X
18 MRM ALND 21 12 IIA Y Y X
19 BCS SLNB   9   1 I Y Y X
Mean±SD 17±11 7.1±7.0
ALND, axillary lymph node dissection; BCS, breast conserving surgery; CT, chemotherapy; HT, hormone therapy; MRM, modified radical mastectomy; 
NACPM, nipple-areola complex preserving mastectomy; RT, radiotherapy; SLNB, sentinel lymph node biopsy.
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tomically located directly deep to the breast, it is possible 
that it would be the most affected muscle by the surgical 
procedure. However, no studies on MTrPs in the subscapu-
laris of post-mastectomy patients are found in the literature. 
The subscapularis muscle, the largest of the rotator cuff 
muscles, acts as a shoulder internal rotator and originates 
from the entire subscapular fossa and inserts onto the lesser 
tuberosity of the humerus. Muscle tension of the subscapu-
laris resulting from immobilization may overwhelm the oth-
er rotator cuff muscles that are relatively weak. As a result, 
internal rotation and adduction contracture of the shoulder 
joint with associated pain occurs frequently.20,21 This can 
lead to reduced external rotation and insufficient acromial 
elevation, provoking rotator cuff tendon impingements.22 
MTrPs in the subscapularis often result from, or are perpet-
uated by, acute or chronic overuse of the muscle, trauma, 
prolonged immobilization (e.g., when the arm is held inter-
nally rotated in a sling or cast), and chronic shortening of 
the muscle (e.g., when the patient has chronic rounded 
shoulders posture with arms internally rotated).9 As MTrPs 
in the subscapularis tend to produce restricted and painful 
the internal rotators of the shoulder.
Hamada, et al.12 documented a case series of 27 patients 
with post-thoracotomy pain, which is often assumed to be 
neuropathic in origin, and found the primary source of pain 
to be MTrPs in 67% of the patients. The authors comment-
ed that the existence of MTrPs significantly increased the 
rate of success after treatment. In a cohort of 163 breast 
cancer patients, 21% also showed active MTrPs.13 One case 
report described the activation of the pectoralis major MTrPs 
as a result of muscle trauma after transaxillary surgery.14 
Given the fact that breast cancer treatment directly involves 
the neuromusculoskeletal tissues of one or more shoulder 
girdle regions, it is not surprising that shoulder pain, limited 
motion, and weakness are frequently reported among breast 
cancer survivors.15-17 Breast cancer survivors in a post-oper-
ative state often display restricted movement of the shoul-
der on the affected side due to pain, tightness related to sur-
gery or radiation, and a general protective tendency resulting 
from fear or anxiety.18,19
Active MTrPs in the pectoralis muscle are most prevalent 
in breast cancer groups.7 As the pectoralis muscle is ana-
Table 2. Changes in Visual Analog Scale (VAS) and Range of Motion (ROM) before and after Treatment
Patient 
No.
No. of 
injections
VAS (1) VAS (2) VAS (3)
ROMER 
(1)
ROMER 
(2)
ROMER 
(3)
ROMAb 
(1)
ROMAb 
(2)
ROMAb 
(3)
  1 1 7 2 4 60 90 80   90 150 150
  2 2 6 2 4 60 80 80 150 175 170
  3 4 9 7 5 30 40 60   80   80   90
  4 3 8 3 2 30 60 75   90 120 150
  5 3 9 5 5 45 60 70 100 110 120
  6 2 6 3 0 70 80 90 170 170 170
  7 3 7 3 3 50 75 80 130 130 150
  8 3 9 4 3 40 60 80   80   90 110
  9 5 8 4 3 45 70 75 110 150 170
10 2 6 2 2 60 70 80 150 170 170
11 3 8 5 3 30 50 75   90 110 150
12 6 6 3 5 50 80 50 150 160 150
13 2 7 4 3 60 80 75 120 150 170
14 4 10 5 4 20 45 45   60   90   90
15 2 6 3 1 60 80 85 160 170 180
16 2 6 3 1 60 80 90 170 170 180
17 1 6 0 2 60 90 85 150 170 180
18 3 7 5 3 50 55 75 110 120 150
19 1 6 1 0 75 85 90 160 170 180
Mean±SD 2.7±1.3 7.2±1.3 3.4±1.6* 2.8±1.5* 50.3±14.9 70.0±15.1* 75.8±12.4* 122.1±34.9 139.7±32.2* 151.6±29.1*
ROMER, external rotation of ROM; ROMAb, abduction of ROM; (1), measures at baseline; (2), measures immediate after the first injection; (3) measures 3 
months after the last injection.
The range of the VAS was 0-10 with 0 meaning no pain and 10 meaning maximal pain, and also that the units of the ROM are in degrees. VAS and ROM 
of the shoulder for external rotation and of abduction showed significant improvement immediate after the first injection and at 3 months after the last 
injection compared with baseline, respectively (*p<0.05).
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of MTrPs in patients with breast cancer did not mentioned 
MTrPs in the subscapularis muscle. This is not because of a 
lack of MTrPs in the subscapularis muscle, but it is more 
likely due to a lack of proper methods for the diagnosis and 
treatment of the subscapularis MTrPs. In addition, we did 
not exclude the patients with adhesive capsulitis. Although 
all participants’ symptoms satisfied MPS criteria, there was 
some overlapping of symptoms which are suggestive of both 
adhesive capsulitis and MPS in shoulder internal rotators. 
Ironically, however, MPS occurs less frequently as a conse-
quence of primary muscle lesion.24-26 Considerable evi-
dence exists to suggest that MPS is frequently caused by or 
related to a lesion in another soft tissue such as adhesive 
capsulitis.26 
In conclusion, the current study shows the existence of 
MTrPs in the subscapularis as well as in the pectoralis mus-
cle in women who had received breast cancer surgery. In 
breast cancer patients with shoulder pain, US-guided trig-
ger point injections of the subscapularis or pectoralis are ef-
fective for both diagnosis and treatment when the cause of 
shoulder pain is suspected to originate from MTrPs in these 
muscles, particularly, the subscapularis. Therefore, we rec-
ommend that MPS should be considered in post-mastecto-
my patients with shoulder pain. Furthermore, since treat-
ment effects decreased when treatment was delayed, initial 
pain severity was high, and limited motion of the shoulder 
was severe for MTrPs of the subscapularis or pectoralis 
muscle in the post-mastectomy state, therefore, early inter-
vention is recommended when MTrPs are suspected in 
these muscles.
SUPPLEMENTARY DATA
Video 1. Trigger point injection of the pectoralis muscle.
Video 2. Trigger point injection of the subscapularis muscle.
REFERENCES
1. Lee SA, Kang JY, Kim YD, An AR, Kim SW, Kim YS, et al. Ef-
fects of a scapula-oriented shoulder exercise programme on upper 
limb dysfunction in breast cancer survivors: a randomized con-
trolled pilot trial. Clin Rehabil 2010;24:600-13. 
2. Ebaugh D, Spinelli B, Schmitz KH. Shoulder impairments and 
their association with symptomatic rotator cuff disease in breast 
cancer survivors. Med Hypotheses 2011;77:481-7. 
3. Cheville AL, Tchou J. Barriers to rehabilitation following surgery 
for primary breast cancer. J Surg Oncol 2007;95:409-18.
external rotation of the arm at the shoulder joint (because 
external rotation of the arm is required for full abduction of 
the arm, arm abduction is also often restricted), MTrPs in 
the subscapularis are often incorrectly assessed as frozen 
shoulder, rotator cuff lesions, cervical disc syndrome, or 
thoracic outlet syndrome.9
Since the subscapularis is located deep between the scap-
ula and the rib cage, diagnosis and treatment of MTrPs in 
the subscapularis muscle are difficult. In the present study, 
we found multiple cases of active MTrPs in the subscapu-
laris muscle of patients with breast cancer using the novel 
US-guided method. The new US-guided technique will 
provide a good safe and accurate approach for diagnosis 
and treatment of MTrPs in the subscapularis muscle.
Ultrasonographic machines are inexpensive, portable, 
and readily accessible as they continue to become standard 
equipment in most hospitals. Ultrasonography is a reliable 
tool that allows for real-time scanning of the targeted struc-
ture, and is useful for detecting LTRs in MTrPs in deeply 
located muscles.11 In addition, US-guidance could facilitate 
depth control during injection for even the deep and less ac-
cessible MTrPs in the subscapularis and reduce potential 
inadvertent injuries that could be caused by improper nee-
dle placement.
There is a case report on blind trigger point injections of 
the subscapularis muscle in patients with diseases other 
than breast cancer,23 and there is also a study to describe an 
US-guided lateral approach for the injection of spastic sub-
scapularis muscle.8 However, we feel that our new US-
guided trigger point injection would be advantageous over 
the older methods, by allowing safe and effective injection 
of MTrPs in the subscapularis muscle.
There are several limitation of our study, including selec-
tion bias, no control group, and the short-term follow-up of 
a small number of patients. Furthermore, we did not find a 
relationship between MTrPs and demographic and clinical 
data such as the type of surgery, type of lymph node dissec-
tion, and use of adjuvant treatments, which are potentially 
important in the development of MTrPs. The present suc-
cess in relieving shoulder pain by trigger point injections 
need to be confirmed with a controlled and long-term stud-
ies involving more patients. Although there were no patients 
in this study who had MTrPs exclusively in the pectoralis, 
not in the subscapularis, our patients group might not re-
flect all those who have had surgery for with breast cancer. 
This study did not address the prevalence of MTrPs in pa-
tients with breast cancer. Previous studies on the prevalence 
Trigger Point Injection for Post-Mastectomy Patients
Yonsei Med J   http://www.eymj.org   Volume 55   Number 3   May 2014 799
Prognosis of the upper limb following surgery and radiation for 
breast cancer. Breast Cancer Res Treat 2008;110:19-37.
16. Levangie PK, Drouin J. Magnitude of late effects of breast cancer 
treatments on shoulder function: a systematic review. Breast Can-
cer Res Treat 2009;116:1-15. 
17. Gyedu A, Kepenekci I, Alic B, Akyar S. Evaluation of muscle at-
rophy after axillary lymph node dissection. Acta Chir Belg 2009; 
109:209-15.
18. Kim SM, Park JM. Normal and abnormal US findings at the mas-
tectomy site. Radiographics 2004;24:357-65.
19. Katz J, Poleshuck EL, Andrus CH, Hogan LA, Jung BF, Kulick 
DI, et al. Risk factors for acute pain and its persistence following 
breast cancer surgery. Pain 2005;119:16-25. 
20. Harrison TP, Sadnicka A, Eastwood DM. Motor points for the 
neuromuscular blockade of the subscapularis muscle. Arch Phys 
Med Rehabil 2007;88:295-7.
21. Yelnik AP, Colle FM, Bonan IV. Treatment of pain and limited 
movement of the shoulder in hemiplegic patients with botulinum 
toxin a in the subscapular muscle. Eur Neurol 2003;50:91-3.
22. Salisbury SK, Choy NL, Nitz J. Shoulder pain, range of motion, 
and functional motor skills after acute tetraplegia. Arch Phys Med 
Rehabil 2003;84:1480-5.
23. Ingber RS. Shoulder impingement in tennis/racquetball players 
treated with subscapularis myofascial treatments. Arch Phys Med 
Rehabil 2000;81:679-82.
24. Chou LW, Hsieh YL, Chen HS, Hong CZ, Kao MJ, Han TI. Re-
mote therapeutic effectiveness of acupuncture in treating myofas-
cial trigger point of the upper trapezius muscle. Am J Phys Med 
Rehabil 2011;90:1036-49. 
25. Hong CZ. Pathophysiology of myofascial trigger point. J Formos 
Med Assoc 1996;95:93-104.
26. Hong CZ, Simons DG. Pathophysiologic and electrophysiologic 
mechanisms of myofascial trigger points. Arch Phys Med Rehabil 
1998;79:863-72.
4. Stubblefield MD, Custodio CM. Upper-extremity pain disorders in 
breast cancer. Arch Phys Med Rehabil 2006;87(3 Suppl 1):S96-9.
5. Torres Lacomba M, Mayoral del Moral O, Coperias Zazo JL, 
Gerwin RD, Goñí AZ. Incidence of myofascial pain syndrome in 
breast cancer surgery: a prospective study. Clin J Pain 2010;26: 
320-5.
6. Simons DG. Review of enigmatic MTrPs as a common cause of 
enigmatic musculoskeletal pain and dysfunction. J Electromyogr 
Kinesiol 2004;14:95-107.
7. Fernández-Lao C, Cantarero-Villanueva I, Fernández-de-Las-Pe-
ñas C, Del-Moral-Ávila R, Menjón-Beltrán S, Arroyo-Morales M. 
Development of active myofascial trigger points in neck and 
shoulder musculature is similar after lumpectomy or mastectomy 
surgery for breast cancer. J Bodyw Mov Ther 2012;16:183-90.
8. Rha DW, Han SH, Kim HJ, Won SY, Lee SC. Ultrasound-guided 
lateral approach for needle insertion into the subscapularis for 
treatment of spasticity. Arch Phys Med Rehabil 2012;93:1147-52.
9. Muscolino JE. The muscle and bone palpation manual with trig-
ger points, referral patterns, and stretching. 1st ed. St. Louis (Mo): 
Mosby Inc; 2009.
10. Simons DG. Muscle pain syndromes--Part I. Am J Phys Med 
1975;54:289-311.
11. Rha DW, Shin JC, Kim YK, Jung JH, Kim YU, Lee SC. Detect-
ing local twitch responses of myofascial trigger points in the low-
er-back muscles using ultrasonography. Arch Phys Med Rehabil 
2011;92:1576-80.
12. Hamada H, Moriwaki K, Shiroyama K, Tanaka H, Kawamoto M, 
Yuge O. Myofascial pain in patients with postthoracotomy pain 
syndrome. Reg Anesth Pain Med 2000;25:302-5.
13. Cheville AL, Troxel AB, Basford JR, Kornblith AB. Prevalence 
and treatment patterns of physical impairments in patients with 
metastatic breast cancer. J Clin Oncol 2008;26:2621-9.
14. Cummings M. Myofascial pain from pectoralis major following 
trans-axillary surgery. Acupunct Med 2003;21:105-7.
15. Lee TS, Kilbreath SL, Refshauge KM, Herbert RD, Beith JM. 
